Moderna Just Gave Investors Another Reason to Buy the Stock

The company's post-pandemic prospects are getting brighter. Moderna (MRNA -3.58%) is best known for its work in the coronavirus vaccine market. That's why the company's stock skyrocketed in the earlier days of the pandemic. It's also why its shares have lagged over the past three years -- its COVID-19 vaccine sales dropped off a cliff. However, the biotech has been looking to move beyond this therapeutic area. It recently earned approval for a vaccine for the respiratory syncytial virus (RSV). Even more rec ...